Total Payments
$13,347
2024 Payments
$1,677
Companies
11
Transactions
42
Medicare Patients
686
Medicare Billing
$107,826
Payment Breakdown by Category
Consulting$7,515 (56.3%)
Travel$4,188 (31.4%)
Food & Beverage$1,448 (10.8%)
Other$134.50 (1.0%)
Education$61.87 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $7,515 | 3 | 56.3% |
| Travel and Lodging | $4,188 | 11 | 31.4% |
| Food and Beverage | $1,448 | 24 | 10.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $134.50 | 2 | 1.0% |
| Education | $61.87 | 2 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $3,951 | 2 | $0 (2021) |
| Merck Sharp & Dohme LLC | $2,855 | 18 | $0 (2024) |
| GENZYME CORPORATION | $2,314 | 2 | $0 (2017) |
| Exelixis Inc. | $2,227 | 8 | $0 (2023) |
| Janssen Biotech, Inc. | $1,363 | 1 | $0 (2023) |
| Dendreon Pharmaceuticals LLC | $262.26 | 5 | $0 (2024) |
| PFIZER INC. | $135.00 | 1 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $111.03 | 2 | $0 (2019) |
| Genentech, Inc. | $57.41 | 1 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $54.57 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,677 | 9 | Merck Sharp & Dohme LLC ($1,528) |
| 2023 | $3,684 | 11 | Exelixis Inc. ($2,227) |
| 2021 | $61.87 | 2 | EMD Serono, Inc. ($51.00) |
| 2020 | $5,273 | 12 | EMD Serono, Inc. ($3,900) |
| 2019 | $336.52 | 6 | Dendreon Pharmaceuticals LLC ($208.20) |
| 2017 | $2,314 | 2 | GENZYME CORPORATION ($2,314) |
All Payment Transactions
42 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 05/31/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 02/07/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $184.75 | General |
| Category: ONCOLOGY | ||||||
| 02/07/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: ONCOLOGY | ||||||
| 02/07/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $59.99 | General |
| Category: ONCOLOGY | ||||||
| 02/07/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $54.99 | General |
| Category: ONCOLOGY | ||||||
| 02/06/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $828.51 | General |
| Category: ONCOLOGY | ||||||
| 02/06/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $184.75 | General |
| Category: ONCOLOGY | ||||||
| 02/06/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 11/17/2023 | Janssen Biotech, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,362.50 | General |
| 06/02/2023 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 02/18/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $54.57 | General |
| Category: Oncology | ||||||
| 01/11/2023 | Exelixis Inc. | — | Food and Beverage | In-kind items and services | $92.24 | General |
| 01/11/2023 | Exelixis Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 01/11/2023 | Exelixis Inc. | — | Food and Beverage | In-kind items and services | $49.49 | General |
| 01/11/2023 | Exelixis Inc. | — | Food and Beverage | In-kind items and services | $49.49 | General |
| 01/10/2023 | Exelixis Inc. | — | Travel and Lodging | In-kind items and services | $1,314.21 | General |
| 01/10/2023 | Exelixis Inc. | — | Travel and Lodging | In-kind items and services | $376.35 | General |
| 01/10/2023 | Exelixis Inc. | — | Travel and Lodging | In-kind items and services | $178.00 | General |
| 01/10/2023 | Exelixis Inc. | — | Travel and Lodging | In-kind items and services | $116.77 | General |
| 10/11/2021 | EMD Serono, Inc. | — | Education | In-kind items and services | $51.00 | General |
| 05/11/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Education | In-kind items and services | $10.87 | General |
| Category: ONCOLOGY | ||||||
| 11/10/2020 | EMD Serono, Inc. | Bavencio (Drug) | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
| Category: Oncology | ||||||
| 02/14/2020 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $57.41 | General |
| 02/12/2020 | Merck Sharp & Dohme Corporation | MK-6482 (Drug) | Travel and Lodging | In-kind items and services | $119.63 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 142 | 197 | $32,438 | $19,345 |
| 2022 | 5 | 169 | 275 | $56,308 | $27,435 |
| 2021 | 6 | 205 | 379 | $79,869 | $38,584 |
| 2020 | 5 | 170 | 276 | $55,884 | $22,462 |
Total Patients
686
Total Services
1,127
Medicare Billing
$107,826
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 33 | 63 | $9,999 | $6,931 | 69.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 27 | $4,302 | $3,008 | 69.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 34 | 41 | $4,400 | $2,918 | 66.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 17 | 17 | $3,497 | $2,505 | 71.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 34 | $3,760 | $2,394 | 63.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $6,480 | $1,590 | 24.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 43 | 77 | $12,810 | $8,609 | 67.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 12 | 45 | $14,670 | $3,740 | 25.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 22 | 35 | $5,675 | $3,705 | 65.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 37 | 49 | $5,335 | $3,643 | 68.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 24 | 38 | $4,180 | $2,825 | 67.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 17 | $10,880 | $2,750 | 25.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 14 | 14 | $2,758 | $2,164 | 78.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 45 | 99 | $16,095 | $11,397 | 70.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 20 | 77 | $25,102 | $6,544 | 26.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 39 | 61 | $6,880 | $4,599 | 66.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 18 | 38 | $6,265 | $4,522 | 72.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 27 | 48 | $5,135 | $3,931 | 76.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 25 | 25 | $5,073 | $3,639 | 71.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 20 | $12,800 | $3,299 | 25.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 11 | 11 | $2,519 | $652.19 | 25.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 30 | 30 | $19,200 | $5,041 | 26.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 46 | 75 | $6,778 | $4,653 | 68.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 29 | 48 | $6,168 | $4,234 | 68.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 32 | 63 | $5,730 | $3,938 | 68.7% |
About Dr. Clara Hwang, M.D
Dr. Clara Hwang, M.D is a Medical Oncology healthcare provider based in Detroit, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/06/2007. The National Provider Identifier (NPI) number assigned to this provider is 1407978505.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Clara Hwang, M.D has received a total of $13,347 in payments from pharmaceutical and medical device companies, with $1,677 received in 2024. These payments were reported across 42 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($7,515).
As a Medicare-enrolled provider, Hwang has provided services to 686 Medicare beneficiaries, totaling 1,127 services with total Medicare billing of $107,826. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Detroit, MI
- Active Since 04/06/2007
- Last Updated 02/09/2009
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1407978505
Products in Payments
- Bavencio (Drug) $3,900
- JEVTANA (Drug) $2,314
- MK-6482 (Drug) $1,316
- PROVENGE (Drug) $262.26
- LYNPARZA (Drug) $54.57
- Xofigo (Drug) $17.29
- KEYTRUDA (Biological) $10.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Detroit
Dr. Ahmed Kaseb, Md, MD
Medical Oncology — Payments: $183,915
Medical Oncology $183,915
Haythem Ali, M.d, M.D
Medical Oncology — Payments: $45,327
Medical Oncology $45,327
Randa Loutfi, M.d, M.D
Medical Oncology — Payments: $5,098
Medical Oncology $5,098
Maria Levitin, M.d, M.D
Medical Oncology — Payments: $257.34
Medical Oncology $257.34
Gerold Bepler, Md, MD
Medical Oncology
Medical Oncology
Ira Wollner, M.d, M.D
Medical Oncology
Medical Oncology